CompletedPhase 2

Liposome Bupivacaine Interscalene Total Shoulder

United States77 participantsStarted 2018-09-17

Plain-language summary

This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult patients aged greater than 18 years of age that are undergoing total or reverse total shoulder arthroplasty Exclusion Criteria: * Patients with allergy to local anesthetics, daily use of opioids for more than 3 weeks prior to surgery, patient refusal, patient with coagulopathy, non-english speaking patients, and those who do not have access to a telephone.

What they're measuring

Total Opioid Use

Timeframe: From end of surgery through 72 hours after end of surgery

Trial details

NCT IDNCT03587636

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-03-15

Results submitted2022-03-21

View on ClinicalTrials.gov More Acute Pain trials